Literature DB >> 18308713

KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals.

Bree Foley1, Dianne De Santis, Louise Lathbury, Frank Christiansen, Campbell Witt.   

Abstract

NK cell cytotoxicity is controlled through a balance of both activating and inhibitory signals. The HLA specificity of alloreactive NK cells has been previously shown to be controlled by inhibitory killer immunoglobulin-like receptors (KIRs). Alloreactive NK cells lyse targets that lack the HLA ligand for their inhibitory KIR. We have characterized in detail an alloreactive NK clone in which the specificity is controlled by an activating receptor, KIR2DS1. Only target cells expressing the HLA-C group 2 (C2) epitope were lysed by this clone and homozygous C2 targets were lysed more strongly than heterozygous C1/C2 targets. Anti-CD158a (KIR2DS1) blocked lysis of targets confirming KIR2DS1 was responsible. Although this NK clone expressed NKG2A, an inhibitory receptor whose ligand is HLA-E, targets with ligands for both KIR2DS1 and NKG2A were lysed by this clone indicating that the KIR2DS1-mediated activation signal overrides the NKG2A-mediated inhibitory signal. KIR2DS1 activated NK clones in polyclonally expanded NK cultures from a donor that lacked the C2 epitope accounted for approximately 1% of all NK cells. This study highlights a potential role for NK cells controlled by activating KIR in mediating NK alloreactivity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308713     DOI: 10.1093/intimm/dxn013

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  30 in total

1.  Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2.

Authors:  Susan E Hiby; Richard Apps; Andrew M Sharkey; Lydia E Farrell; Lucy Gardner; Arend Mulder; Frans H Claas; James J Walker; Christopher W Redman; Christopher C Redman; Linda Morgan; Clare Tower; Lesley Regan; Gudrun E Moore; Mary Carrington; Ashley Moffett
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

Review 2.  Clinical utility of natural killer cells in cancer therapy and transplantation.

Authors:  David A Knorr; Veronika Bachanova; Michael R Verneris; Jeffrey S Miller
Journal:  Semin Immunol       Date:  2014-03-05       Impact factor: 11.130

3.  The activating Ly49W and inhibitory Ly49G NK cell receptors display similar affinities for identical MHC class I ligands.

Authors:  Brian J Ma; Carla M Craveiro Salvado; Kevin P Kane
Journal:  Immunogenetics       Date:  2014-05-07       Impact factor: 2.846

Review 4.  Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias.

Authors:  A Moretta; D Pende; F Locatelli; L Moretta
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

5.  The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.

Authors:  Alexander Hallner; Elin Bernson; Brwa Ali Hussein; Frida Ewald Sander; Mats Brune; Johan Aurelius; Anna Martner; Kristoffer Hellstrand; Fredrik B Thorén
Journal:  Blood       Date:  2019-01-15       Impact factor: 22.113

6.  Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation.

Authors:  Shiqiu Xiong; Andrew M Sharkey; Philippa R Kennedy; Lucy Gardner; Lydia E Farrell; Olympe Chazara; Julien Bauer; Susan E Hiby; Francesco Colucci; Ashley Moffett
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

Review 7.  Structural insights into activation of antiviral NK cell responses.

Authors:  Kathryn A Finton; Roland K Strong
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

Review 8.  The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).

Authors:  Bree Foley; Martin Felices; Frank Cichocki; Sarah Cooley; Michael R Verneris; Jeffrey S Miller
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

9.  NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand.

Authors:  Gianfranco Pittari; Xiao-Rong Liu; Annamalai Selvakumar; Zeguo Zhao; Ernesto Merino; Morgan Huse; Joseph H Chewning; Katharine C Hsu; Bo Dupont
Journal:  J Immunol       Date:  2013-04-03       Impact factor: 5.422

Review 10.  The Yin and Yang of HLA and KIR in human disease.

Authors:  Smita Kulkarni; Maureen P Martin; Mary Carrington
Journal:  Semin Immunol       Date:  2008-07-16       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.